| Autor: |
Ji TT; Department of Hematology，Huai'an First People's Hospital Affiliaed to Nanjing Medical University，Huai'an 223300, Jiangsu Province，China,Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China., Chen QN; Department of Hematology，Huai'an First People's Hospital Affiliaed to Nanjing Medical University，Huai'an 223300, Jiangsu Province，China,Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China., Tao SD; Department of Hematology，Huai'an First People's Hospital Affiliaed to Nanjing Medical University，Huai'an 223300, Jiangsu Province，China,Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China., Yu L; Department of Hematology，Huai'an First People's Hospital Affiliaed to Nanjing Medical University，Huai'an 223300, Jiangsu Province，China,Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China,E-mail: yuliangha@163.com. |
| Abstrakt: |
Abstract Spleen tyrosine kinase (SYK) is not only a key kinase in the B-cell receptor (BCR) signaling pathway, but also a critical component of other signal transduction pathways such as Fc receptor, complement receptor and integrin. Abnormal activation of SYK closely related to the occurrence and development of hematological malignancies, thus targeting SYK has become a research hotspot. Several SYK inhibitors including Fostamatinib, Entospletinib and Cerdulatinib were being evaluated in clincal trials. As a second generation SYK inhibitor, Entospletinib has achieved good efficacy in lymphoid and myeloid hematologic tumors. Furthermore, Entospletinib can significantly relieve hematopoietic stem cell transplantation(HCT) related graft versus host disease (GVHD). In this review the role of SYK inhibitors in treatment of hematological malignancies is summarized brifely. |
